Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.
Latest From Pricing Debate
Amid an escalating tussle with the health ministry over the level of South Korean drug prices, foreign pharma firms operating in the country are now proposing the launch of a new joint study on the issue with the incoming government.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Former Obama Administration official offers sophisticated and complicated approach to value-based pricing, tied back to drug development costs. The complexity alone makes the idea a non-starter for the current Administration, but it also begs the question of whether it would be more likely to cut costs – or just increase R&D spending?
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.
Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.
The Australian government has promised not to implement any new therapeutic groups under the Pharmaceutical Benefits Scheme for the next five years, nor will it introduce any new pricing reforms without consulting the innovative drug industry first.
While other companies have promised not to raise their drug prices beyond 10%, Sanofi is using the rate of medical inflation (expected to be 5.4% in 2017) in setting its annual list price hikes. Company retains option to increase prices beyond benchmark.
Wall Street Journal brings Marathon Pharmaceuticals back to the front pages – but this time to report that the company is expected to shut down after a 'drug-price revolt.' The rest of the industry should hope the headline catches the President’s eye.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.